Tysabri growth continues at pace for Biogen Idec
20 April 2009
Simon Varcoe
Please Login to read the full article.
20 April 2009
Simon Varcoe
simon.varcoe@informa.com
Biogen Idec's first-quarter revenue leapt by 10% to $1.04 billion, driven by another strong performance by the multiple sclerosis drug Tysabri (natalizumab).
The company's revenue from Tysabri, also marketed by
Elan, increased by 44% to $165.2 million compared with the first quarter of last...
Please Login to read the full article.
RELATED CONTENT
FEATURES
Other Informa Features
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
